44 results about "Tumour development" patented technology

The invention provides a breast cancer circulating tumor cell line CTC-3, a culture medium, and a building method and application of the CTC-3, and relates to the technical field of cells. The collection number of the breast cancer circulating tumor cell line CTC-3 provided by the invention is CCTCC NO: C201892. The character of the cell line is stable, and large-scale basic researches and clinical tests can be developed, thereby further mastering features of a circulating tumor cell and explaining a tumor development mechanism, and providing a basis for clinical staging, prognosis and individualized treatment for a cancer patient. The culture medium provided by the invention comprises a basic culture medium and an additive. The culture medium can greatly multiply high-quality and high-purity circulating tumor cells. The building method of the breast cancer circulating tumor cell line CTC-3 is easy to operate, low in cost and wide in universality, and can quickly and effectively realize multiplication culture of the breast cancer circulating tumor cells.

The invention discloses a novel tumor marker GSTA1 for lung cancer as well as a screening method and application thereof, belonging to the field of molecular biology and medical science. The marker is characterized in that on the basis of the novel lung cancer specific binding polypeptide acquired by utilizing a bacteriophage random peptide library screening technology at the earlier stage, the polypeptide is used as a probe to select lung cancer associated antigen GSTA1 from a lung cancer cDNA library. The occurrence and development of the lung cancer have a complicated mechanism, the lung cancer involves to the alteration of a lot of lung cancer associated genes and expressions thereof in the primary stage, a plurality of adhesion molecules as well as receptors or ligands can be expressed in a patient body under the effect of a carcinogenic factor, the content of the marker released by the tumor at different development stages is also different, the variation of the specific molecular marker of the tumor cancer is detected from peripheral blood and sputum, advantages of simplicity, rapidness, little pain and easiness in reviewing can be achieved, the novel tumor marker GSTA1 is easy to receive by the patient, and an important significance on the clinical diagnosis for the lung cancer can be achieved. The molecular marker can be provided for the diagnosis and targeted therapy of the lung cancer, a candidate antigen can be provided for the research of the lung cancer tumor vaccine, and the application prospect is wide.

The present invention includes a diagnostic assay for the detection and determination of MGP in a human serum sample, which comprises the use of one or more antibodies, preferably monoclonal antibodies, specifically recognizing epitopes on and/or conformations of human Matrix Gla-Protein. A method is provided for using MGP-related antigens as biomarkers for certain diseases, for example, atherosclerosis and other vascular diseases, and angiogenesis/neogenesis in tumor development. Monoclonal antibodies of class IgG are described for use in the assay, which are defined herein as mAb3-15, mAb35-49[Glu], mAb35-49[Gla], mAb35-53[Glu], and mAb35-53[Gla]. Polyclonal antibodies and methods are also disclosed for measuring MGP in a human serum sample.

The invention features tumor antigens; tumor antigen-encoding nucleic acids; antibodies specific for tumor antigens and methods of using the antibodies; methods of identifying tumor antigens and the nucleic acids that encode them; methods of monitoring or diagnosing tumors in patients; methods of testing patients for the increased likelihood of developing a tumor; and methods and compositions for treatment of a tumor or prophylaxis against developing a tumor.

The present disclosure concerns LNA oligonucleotides having a (sub)sequence of the general formula 5'- ( Me Cx )(Tx,) Me CXAs Astscscsastsgsgs MeCXAX (G x) (c)-3',and preferably of the general formula 5'- Me C XTX), MeCXAsastscscsastsgsgs Me CxAx G x c-3', wherein capital letters designate a n LNA nucleotide analogue selected from .beta. -D-oxy-LNA, .beta. -D-thio-LNA, .beta.-D-amino-LNA and a-L-oxy-LNA, small letters designate a deoxynucleotid e, and underline designates either an LNA nucleotide analogue as defined above or a deoxynucleotide. Such LNA oligonucleotides exhibit surprisingly good properties with respect to inhibition of the expression of Survivin by means of an anti-sense mechanism, and thereby lead to reduction or inhibition of tumour development in vivo. The LNA oligonucleotides are superior to other L NA oligonucletides targeting Surviving mRNA measured by functional read outs such as apoptosis induction and proliferation inhibition, and is potent in down- regulating Survivin mRNA and protein in transfected cancer cell lines, and induce apoptosis in combination with Taxol superior compared to other LNA oligonucleotides.

The invention provides compositions comprising IGFBP-4 and methods for inhibiting angiogenesis and tumor development processes, and for treating angiogenesis-dependent conditions, using an insulin growth factor binding protein, IGFBP-4.

The invention relates to the use of inhibitors of the expressed proteins of the murine genes and/or their human homologues listed in Table 1 for the preparation of a therapeutical composition for the treatment of cancer, in particular for the treatment of solid tumors of lung, colon, breast, prostate, ovarian, pancreas and leukemia and the use of the genes listed in Table 1 for the diagnosis of cancer. The invention also relates to the therapeutical compositions comprising the inhibitors and to methods for development of the inhibitor compounds.

The present invention relates to products and compositions containing (i) a chemotherapeutic agent and (ii) at least an active compound chosen from CCL2 inhibitors, CCR2 inhibitors, NF-κB inhibitors, PARP-1 inhibitors and ATM inhibitors, as a combined preparation for simultaneous, separate or sequential use for inhibiting tumor development caused by tumor cell senescence induced by said chemotherapeutic agent. The invention also refers to a method for monitoring the response to a chemotherapeutic agent of a patient suffering from a cancer, and to a method for predicting the tumor size evolution and/or the onset of metastasis in a patient suffering from a cancer.

Treatment of tumors, especially breast cancer or glioblastoma tumors, by silencing RAB27A and/or TRAF3IP2, compositions and methods for same.

5′-methylthioadenosine (MTA) is described as a compound that is susceptible to inhibiting and/or blocking the epithelial-mesenchymal transition (EMT), a process whereby epithelial cells become mesenchymal cells.

The periodical intake of MTA [every 24 h for 21 days] significantly improves fibrosis and the markers for hepatic cellular damage in KO-Mdr2 mice with MTA (28 mg/kg). Following the daily oral administration of MTA, both the expression of EMT markers in the total liver and appreciable signs of fibrosis are significantly reduced, indicating the beneficial effect of MTA on the liver affected by the lack of Mdr2. MTA is proposed to be a safe drug, suitable for oral formulation and without secondary effects, to be used in the prevention and/or treatment of diseases associated with EMT, including chronic cholestatic diseases, fibrosis and cholangiocarcinoma. On the other hand, MTA is proposed for application in anti-tumor therapies by inhibiting or blocking the EMT properties of CSC cells, in order to improve the prognosis of tumor development and the malignancy thereof.

The invention belongs to the technical field of bioinformatics, and discloses a non-differential gene associated with tumor cell malignant phenotypes and a screening method and application thereof, the non-differential gene interacts with a plurality of differential genes of cancerous tissues, is ubiquitous in the cancerous tissues and para-carcinoma tissues, has relatively high abundance expression and no differential expression, and can be used for screening tumor cell malignant phenotypes. And the characteristic of playing a heavy role in a network path is realized. And sorting the genes to be distinguished through an SVM model for distinguishing cancerous tissues and para-carcinoma tissues, and removing differential genes from the genes at the first 5% of the sorted genes to obtain the non-differential genes. With the non-differential gene as a target, the non-differential gene can be used for preparing drugs for preventing or treating tumors related to the non-differential gene. Whether the non-differential genes are knocked down for preventing tumors or knocked down after tumors are formed for controlling tumor development, the screened non-differential genes can inhibit the sizes of mice tumors.

The invention discloses a KRAS high-expression cancer vaccine based on recombinant attenuated Listeria monocytogenes and a preparation method and application method thereof. The cancer vaccine is bacterial liquid of an Lm delta actA/ plcB-KRAS strain; the Lm delta actA/ plcB-KRAS strain is a gene recombinant bacterium carrying a KRAS protein gene by taking the attenuated Listeria monocytogenes asa carrier; the attenuated Listeria monocytogenes is obtained by completely knocking out two virulence genes of actA and plcB from the Listeria monocytogenes; and the KRAS protein gene is a DNA sequence obtained by synthesizing a KRAS protein amino acid sequence after being optimized by a Listeria codon, adding a Hind III restriction enzyme cutting site at the upstream and adding an Xho I restriction enzyme cutting site at the downstream. According to the KRAS high-expression cancer vaccine disclosed by the invention, the attenuated Listeria monocytogenes is used as the carrier, and the specific immune response in a tumor microenvironment is effectively improved by utilizing the characteristic that the Listeria monocytogenes can uniquely grow in a host phagocyte and is a natural T cell immune activation adjuvant, so that the immune tolerance of an organism is broken, and further the development of tumors can be inhibited.

The invention discloses an application of lncRNA (long non-coding ribonucleic acid) SLC25A21-AS1 as a marker of esophageal squamous cell carcinoma. The invention provides application of a substance for detecting the expression quantity of LncRNA SLC25A21-AS1 in at least one of the following functions or preparation of a product with at least one of the following functions: (1) a product for predicting the prognosis state of a patient with esophageal squamous carcinoma; (2) predicting the postoperative recurrence-free survival rate of the esophageal squamous carcinoma patient; (3) predicting the overall survival rate of the esophageal squamous carcinoma patient after operation; (4) predicting the tumor differentiation degree of the esophageal squamous carcinoma patient; experiments prove that the lncRNA SLC25A21-AS1 is used as the lncRNA for promoting tumor development, can influence the progress of esophageal squamous cell carcinoma through multiple ways, and prompts that the lncRNA SLC25A21-AS1 has the multifunctional characteristic, but the expression is reduced under the influence of high fat diet or palmitic acid.

The invention discloses a traditional Chinese medicine capsule for replacing cancer postoperative chemotherapy. The invention relates to an anti-cancer traditional Chinese medicine capsule capable of clearing away heat and toxic materials and reducing or replacing the postoperative chemotherapy course of a cancer patient. The anti-cancer traditional Chinese medicine capsule is prepared from 15%-15.5% of taxus chinensis seeds, 7.5%-7.75% of stichopus japonicus, 7.5%-7.75% of paris polyphylla, 7.5%-7.75% of semen strychni, 7.5%-7.75% of oldenlandia diffusa, 7.5%-7.75% of pangolin scales, 7.5%-7.75% of gecko, 7.5%-7.75% of scorpio, 7.5%-7.75% of centipede, 15%-15.5% of dandelion and 7.5%-7.75% of liquorice. The traditional Chinese medicine composition has the advantages that malignant tumor development can be inhibited in a mode of combating poison with poison, the effect of replacing postoperative chemotherapy is achieved, the immunity of a patient can be improved by curing cancerous cells, and then cancer cells are inhibited and cured by relying on the immunity of the patient.

The invention relates to a nano preparation for treating multidrug resistance tumours, a composition and application of the nano preparation and the composition. Tumour drug resistance is a main reason of current clinical chemotherapy failure; and in order to realize a drug resistance tumour reversal effect, the invention provides a nano preparation for drug resistance tumours and a preparation method of the nano preparation, wherein the nano preparation is a pharmaceutical composition of paclitaxel and resveratrol; and the nano preparation with a bionic structure is constructed through a pH-sensitive lipid material and a targeting material. Through verification, the nano preparation has a good entrapment effect and physicochemical properties, and shows good pH responsiveness in in-vitro release. Animal experiments prove that the nano preparation can effectively inhibit the tumour development process, is higher in safety when applied to animal bodies, is expected to be applied to clinical treatment and overcomes the defects of chemical medicine treatment.

The present invention provides methods of delaying development of CEA-associated tumors using the anti-idiotype antibody 3H1, particularly in high-risk individuals.

The invention relates to an application of a 3'-sulfo-Lea antigen in preparing a tumour detection reagent, belonging to the field of molecular biology. The invention detects the level of the 3'-sulfo-Lea antigen of a blood serum through an enzyme linked immunosorbent assay, regulates a galactose sulfonyl transferase synthesizing the 3'-sulfo-Lea antigen downwards by applying an RNAi (RNA interference) technology, observes the variation of the migration capacity of gastric adenocarcinoma cells of human through an agar drip migration test and the variation of cell adhesion capability through an adhesion test of the cells, umbilical vein endothelial cells and the sL-selectin of human , acts chemotherapy drugs 5-FU and antitumor drugs on the gastric adenocarcinoma cells of human through concentration and time gradient and detects the variation of the expression level of the 3'-sulfo-Lea antigen contained in a whole cell lysis solution. A result shows that 3'-sulfo-Lea antigen level is correlated with the development of gastric cancers and colorectal cancers; in addition, the invention influences the expression of the 3'-sulfo-Lea antigen and then can regulate the biological behaviors of tumour cells, which are correlated with transfer. The 3'-sulfo-Lea antigen can be further used for preparing a reagent and a kit which are used for detecting tumour development.